Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma

Acta Oncologica

Volumn 51, Issue 5, 2012, Pages 687-688

  Crouzet, Laurence ^a   Edeline, Julien ^a   Du, Fanny Le ^a   Boucher, Eveline ^a   Audrain, Odile ^a   Raoul, Jean Luc ^b  

^a CENTRE EUGÈNE MARQUIS   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; FATALITY; FEVER; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; JAUNDICE; LETTER; LOW BACK PAIN; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; PRIORITY JOURNAL; RASH; SHIVERING; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; URINE COLOR;

ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DISEASE PROGRESSION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; JAUNDICE; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84862114507     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.661073     Document Type: Letter

References (10)

1. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362: 1273-81.
2. Andr éT, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: A phase II study. Br J Cancer 2008;99:862-7.
3. Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del GF, et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006;17(Suppl 5):v72 - 8.
4. Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664-70.
5. Amirlak I, Amirlak B. Haemolytic uraemic syndrome: An overview. Nephrology (Carlton) 2006;11:213-8.
6. Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, Fremeaux- Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009;101:227-32.
7. Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher 2009;24:209-14.
8. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: Case report. BMC Clin Pharmacol 2006;6:5.
9. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: Two case reports and a review of the literature. J Hematol Oncol 2010;3:12.
10. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2 ¢ ,2 ¢ -difl uorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117-23.